Lab of Biorefinery, Shanghai Advanced Research Institutegrid.458506.a, Chinese Academy of Sciences, Pudong, Shanghai, China.
School of Life Science and Technology, ShanghaiTech University, Pudong, Shanghai, China.
Appl Environ Microbiol. 2022 Nov 22;88(22):e0130322. doi: 10.1128/aem.01303-22. Epub 2022 Oct 26.
Steroid drug precursors, including C19 and C22 steroids, are crucial to steroid drug synthesis and development. However, C22 steroids are less developed due to the intricacy of the steroid metabolic pathway. In this study, a C22 steroid drug precursor, 9-hydroxy-3-oxo-4,17-pregadiene-20-carboxylic acid methyl ester (9-OH-PDCE), was successfully obtained from Mycolicibacterium neoaurum by 3-ketosteroid-Δ-dehydrogenase and enoyl-CoA hydratase ChsH deficiency. The production of 9-OH-PDCE was improved by the overexpression of 17β-hydroxysteroid dehydrogenase Hsd4A and acyl-CoA dehydrogenase ChsE1-ChsE2 to reduce the accumulation of by-products. The purity of 9-OH-PDCE in fermentation broth was improved from 71.7% to 89.7%. Hence, the molar yield of 9-OH-PDCE was improved from 66.7% to 86.7%, with a yield of 0.78 g/L. Furthermore, enoyl-CoA hydratase ChsH1-ChsH2 was identified to form an indispensable complex in DSM 44704. C22 steroids are valuable precursors for steroid drug synthesis, but the development of C22 steroids remains unsatisfactory. This study presented a strategy for the one-step bioconversion of phytosterols to a C22 steroid drug precursor, 9-hydroxy-3-oxo-4,17-pregadiene-20-carboxylic acid methyl ester (9-OH-PDCE), by 3-ketosteroid-Δ-dehydrogenase and enoyl-CoA hydratase deficiency with overexpression of 17β-hydroxysteroid dehydrogenase acyl-CoA dehydrogenase in . The function of the enoyl-CoA hydratase ChsH was revealed. Construction of the novel C22 steroid drug precursor producer provided more potential for steroid drug synthesis, and the characterization of the function of ChsH and the transformation of steroids further revealed the steroid metabolic pathway.
甾体药物前体,包括 C19 和 C22 甾体,是甾体药物合成和开发的关键。然而,由于甾体代谢途径的复杂性,C22 甾体的发展较少。在这项研究中,通过 3-酮类固醇-Δ-脱氢酶和烯酰辅酶 A 水合酶 ChsH 缺陷,从耻垢分枝杆菌中成功获得了 C22 甾体药物前体 9-羟基-3-氧代-4,17-孕二烯-20-羧酸甲酯(9-OH-PDCE)。通过过表达 17β-羟甾脱氢酶 Hsd4A 和酰基辅酶 A 脱氢酶 ChsE1-ChsE2 来减少副产物的积累,提高了 9-OH-PDCE 的产量。发酵液中 9-OH-PDCE 的纯度从 71.7%提高到 89.7%。因此,9-OH-PDCE 的摩尔收率从 66.7%提高到 86.7%,产量为 0.78g/L。此外,还鉴定了烯酰辅酶 A 水合酶 ChsH1-ChsH2 在 DSM 44704 中形成不可缺少的复合物。C22 甾体是甾体药物合成的有价值前体,但 C22 甾体的发展仍不尽如人意。本研究提出了一种策略,通过 3-酮类固醇-Δ-脱氢酶和烯酰辅酶 A 水合酶缺陷,以及在 过表达 17β-羟甾脱氢酶酰基辅酶 A 脱氢酶,一步生物转化植物甾醇为 C22 甾体药物前体 9-羟基-3-氧代-4,17-孕二烯-20-羧酸甲酯(9-OH-PDCE)。揭示了烯酰辅酶 A 水合酶 ChsH 的功能。新型 C22 甾体药物前体生产菌的构建为甾体药物合成提供了更多潜力,ChsH 功能的表征和甾体的转化进一步揭示了甾体代谢途径。